| Popis: |
Tetsuo Tani,1– 3 Ichiro Nakachi,1,4 Shinnosuke Ikemura,1 Shigenari Nukaga,1,5 Keiko Ohgino,1,6 Aoi Kuroda,1,7 Hideki Terai,1,8 Keita Masuzawa,1,8 Taro Shinozaki,1 Kota Ishioka,1,9 Yohei Funatsu,1,2 Hidefumi Koh,1,2 Koichi Fukunaga,1 Kenzo Soejima1,10 On behalf of the Keio Lung Oncology Group (KLOG)1Department of Medicine, Keio University School of Medicine, Tokyo, Japan; 2Department of Internal Medicine, Tachikawa Hospital, Tokyo, Japan; 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 4Department of Internal Medicine, Saiseikai Utsunomiya Hospital, Utsunomiya, Tochigi, Japan; 5Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan; 6Department of Pulmonary Medicine, Kawasaki Municipal Hospital, Kawasaki, Kanagawa, Japan; 7Department of Respiratory Medicine, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan; 8Department of Pulmonary Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan; 9Department of Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan; 10Clinical and Translational Research Center, Keio University Hospital, Tokyo, JapanCorrespondence: Ichiro NakachiDepartment of Internal Medicine, Saiseikai Utsunomiya Hospital, 911-1 Takebayashimachi, Utsunomiya, Tochigi, 321-0974, JapanTel +81- 28-626-5500Fax +81- 28-626-5594Email nichiro4747@gmail.comBackground: Metastatic peritoneal carcinomatosis (MPC) is not common in patients with non-small cell lung cancer (NSCLC), and the clinical characteristics and treatment outcomes are still unclear.Patients and Methods: We recruited 46 NSCLC patients with MPC at Keio University and affiliated hospitals (Keio Lung Oncology Group) between January 2011 and December 2017, then retrospectively investigated their clinical characteristics and the impact of treatment interventions on their survival.Results: The profile of histological subtype was predominantly adenocarcinoma and 15 patients harbored driver oncogenes. Univariate and multivariate analysis demonstrated that performance status and the presence of a driver oncogene were significantly associated with the prolonged overall survival (OS). Regarding treatment, the median OS in the treatment group (9.3 months) was significantly longer than in the best supportive care group (1.3 months) (P < 0.0001).Conclusion: The prognosis of MPC in NSCLC patients who receive only the best supportive care is poor, but therapeutic intervention may improve prognosis.Keywords: metastatic peritoneal carcinomatosis, NSCLC, EGFR, malignant ascites, peritoneal nodule, intraperitoneal dissemination |
